Share on StockTwits
 

Victrex (LON:VCT)‘s stock had its “overweight” rating restated by Barclays Capital in a research note issued on Thursday, Analyst Ratings Network reports. They currently have a GBX 1,860 ($30.01) price target on the stock. Barclays Capital’s price target suggests a potential upside of 16.91% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex (LON:VCT) in a research note to investors on Monday. They now have a GBX 1,400 ($22.59) price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Victrex (LON:VCT) from GBX 1,500 ($24.20) to GBX 1,550 ($25.01) in a research note to investors on Wednesday, September 4th. They now have a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,661.54 ($26.81).

Victrex (LON:VCT) traded down 0.57% during mid-day trading on Thursday, hitting GBX 1582.00. 52,147 shares of the company’s stock traded hands. Victrex has a one year low of GBX 1331.00 and a one year high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.332 billion.

Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.